Poloni Antonella, Costantini Benedetta, Mariani Marianna, Leoni Pietro
Dipartimento di Scienze Cliniche e Molecolari, Clinica di Ematologia, Università Politecnica delle Marche, Ancona, Italy.
Leuk Res Rep. 2013 Jun 11;2(2):44-6. doi: 10.1016/j.lrr.2013.03.003. eCollection 2013.
Myelodysplastic syndromes are heterogeneous myeloid neoplasms ranging from indolent conditions with a near-normal life expectancy to forms approaching acute myeloid leukemia. Here we report a 51-year-old woman with depression and severe obesity who was diagnosed with an International Prognostic Scoring System low-risk myelodysplastic syndrome, presenting mainly with thrombocytopenia, treated with escalating dose of valproic acid as a single agent. After two years of treatment her platelet count is almost normal and the tolerance to therapy is good. It is already known that valproic acid could be used in high-risk myelodysplastic syndromes and acute myeloid leukemia, mainly in association with other drugs, but its role in low-risk myelodysplastic syndrome is not well established yet.
骨髓增生异常综合征是一组异质性的髓系肿瘤，范围从生存期接近正常的惰性疾病到接近急性髓系白血病的类型。在此，我们报告一名51岁患有抑郁症和严重肥胖的女性，她被诊断为国际预后评分系统低危骨髓增生异常综合征，主要表现为血小板减少，接受递增剂量丙戊酸单药治疗。经过两年治疗，她的血小板计数几乎正常，对治疗的耐受性良好。已知丙戊酸可用于高危骨髓增生异常综合征和急性髓系白血病，主要是与其他药物联合使用，但其在低危骨髓增生异常综合征中的作用尚未明确。
